What do systematic reviews say?

Low molecular weight heparin vs unfractionated heparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

Capecitabine‐containing regimens showed no clear difference in febrile neutropenia compared with non‐capecitabine‐containing regimens (moderate certainty).

• Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
  OR 1.31 [0.97, 1.77]
  4 studies · 2890 participants
  Moderate

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

• Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
  OR 0.55 [0.47, 0.64]
  5 studies · 8086 participants
  Moderate

Mycophenolate mofetil vs levamisole

It is very uncertain whether mycophenolate mofetil changes adverse effects: leukopenia compared with levamisole (very low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 2.88 [0.12, 69.65]
  1 study · 149 participants
  Very low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in adverse effects: lymphopenia compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.64 [0.08, 4.85]
  2 studies · 84 participants
  Low

Levamisole vs steroids or placebo or both, or no treatment

Levamisole showed no clear difference in adverse effects: leucopenia compared with steroids or placebo or both, or no treatment (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 4.18 [0.72, 24.21]
  3 studies · 214 participants
  Low

Levamisole vs cyclophosphamide

Levamisole showed no clear difference in adverse effects: leucopenia compared with cyclophosphamide (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.25 [0.04, 1.48]
  2 studies · 97 participants
  Low

Alkylating agents vs cyclosporin

It is very uncertain whether alkylating agents changes adverse effects: leucopenia compared with cyclosporin (very low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 29.84 [1.84, 483.93]
  1 study · 66 participants
  Very low

Alkylating agents vs steroids, placebo or both

Alkylating agents led to higher CPA: leucopenia compared with steroids, placebo or both; GRADE not reported.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 10.63 [1.45, 78.05]
  Studies not reported
  GRADE not reported

Alkylating agents vs steroids, placebo or both

Alkylating agents showed no clear difference in chlorambucil: leucopenia compared with steroids, placebo or both; GRADE not reported.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 2.5 [0.11, 54.87]
  Studies not reported
  GRADE not reported

Intravenous vs oral cyclophosphamide

Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.37 [0.09, 1.51]
  2 studies · 83 participants
  Low

Cyclophosphamide vs chlorambucil

Cyclophosphamide may leads to lower adverse effects: lymphopenia compared with chlorambucil (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.43 [0.21, 0.87]
  1 study · 50 participants
  Low

Cyclophosphamide vs chlorambucil

Cyclophosphamide may leads to lower adverse effects: thrombocytopenia compared with chlorambucil (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.43 [0.21, 0.87]
  1 study · 50 participants
  Low

Intervention not reported

• Interventions to slow progression of myopia in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Moderate

Carboplatin vs cisplatin chemotherapy

Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).

• Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
  RR 2.46 [1.49, 4.04]
  10 studies · 3857 participants
  Moderate

Unfractionated heparin vs low molecular weight heparin

It is very uncertain whether unfractionated heparin changes thrombocytopenia compared with low molecular weight heparin (very low certainty).

• Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
  RR 0.57 [0.2, 1.63]
  2 studies · 124 participants
  Very low

Unfractionated heparin vs no pharmacological anticoagulation

The review found no eligible studies for this question.

• Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Citrate vs unfractionated heparin

Citrate showed no clear difference in thrombocytopenia compared with unfractionated heparin (low certainty).

• Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
  RR 0.39 [0.14, 1.03]
  3 studies · 412 participants
  Low

HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day)

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day)

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found